Zymeworks, a early-stage biotech developing bispecific antibodies that target HER2 tumors, raised $59 million by offering 4.5 million shares at $13, the low end of the range of $13 to $16. Zymeworks plans to list on the NYSE under the symbol ZYME. Citi, Barclays and Wells Fargo Securities acted as lead managers on the deal.
